We ask MIT’s Vander Heiden to delineate science from engineering—and NCI from ARPA-H

“The lines are much more blurred in terms of what’s an engineering problem and what’s a basic science problem.”

By Matthew Bin Han Ong and Paul Goldberg

We ask MIT’s Vander Heiden to delineate science from engineering—and NCI from ARPA-H “The lines are much more blurred in terms of what’s an engineering problem and what’s a basic science problem.”

The boundary between basic science and engineering has been the subject of animated discussions in cancer research for quite some time. Where does science end and engineering begin? Is that boundary porous? How does it shift over time?

We ask MIT’s Vander Heiden to delineate science from engineering—and NCI from ARPA-H

Herd immunity is achievable, but it will be tight, Francis Collins, other AACR panelists say

Chernobyl: a 35 year follow up on long-term health effects

Vincent T. DeVita, Jr. on the National Cancer Act: “Money does buy ideas”

In Brief

Taofeek K. Owonikoko named chief of Hematology/Oncology at UPMC Hillman

Suresh S. Ramalingam named editor-in-chief of Cancer

Douglas S. Tyler elected 2021-2022 president of SSO

SU2C receives $4 from Mirati for KRAS mutant cancer research

UAMS Winthrop P. Rockefeller Cancer Institute recognizes two Little Rock Central High Students

Funding Opportunities

DoD Rare Cancers Research Program anticipated funding opportunities for FY21

Clinical Roundup

Roswell Park, Wilmot Cancer Institute collaborate on large study of immunotherapy in Black cancer patients

City of Hope develops a noninvasive liquid biopsy identifying lymph node metastasis in T1 colorectal cancer

Yale Cancer Center researchers identify common mechanism causing autoimmune disease and blood cancers

Yale Cancer Center researchers identify new role for immune-boosting protein “STING” in head and neck cancer

AI could create better outcomes for bowel cancer patients

Drugs & Targets

Jemperli receives FDA accelerated approval for endometrial cancer

Opdivo + chemo regimen gets FDA approval for metastatic gastric cancer, esophageal adenocarcinoma indications

Bemarituzumab receives Breakthrough Therapy designation from FDA

European Commission approves second indication of Sarclisa for relapsed multiple myeloma

NeoGenomics establishes Biomarker Assist KRAS Single Gene Testing Program for advanced NSCLC

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login